Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407431 · ClinicalTrials.gov registry record
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by University of Pittsburgh.
- Active
- Registry status
- 1,000
- Enrollment target
- 5
- Study locations
NCT02407431: Active study of Idiopathic Pulmonary Fibrosis, sponsored by University of Pittsburgh.
NCT02407431 is a study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 1,000 participants, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407431, a study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by University of Pittsburgh.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
Primary Outcome
Create the PaTH Network IPF Clinician-Patient Partnership Cohort, which will allow the conduct of patient-centered observational studies on IPF across the multiple institutions (Hershey Penn State, University of Pittsburgh, Temple University) of the PaTH network.
Conditions Studied
Study Locations (5)
Pennsylvania
- Jody McCullough - Hershey
- Anuradha Paranjape - Philadelphia
- University of Pittsburgh - Pittsburgh
Maryland
- Johns Hopkins University - Baltimore
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2015-03 |
| Est. Completion | 2030-07 |
What the registry record for NCT02407431 still lists
NCT02407431 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT02407431 lists 5 locations in 3 states (Pennsylvania, Maryland, Utah).
Frequently Asked Questions
What is clinical trial NCT02407431 about?
NCT02407431 is a clinical study titled "PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort". The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
What is the current status of trial NCT02407431?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2015-03. Estimated completion is 2030-07.
What conditions does trial NCT02407431 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
Who is sponsoring clinical trial NCT02407431?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407431 being conducted?
This trial has 5 study locations across Maryland, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02407431's enrollment target sits among peer trials
1,000 7th of 51 higher than 44 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma